Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT02844218|
Recruitment Status : Completed
First Posted : July 26, 2016
Last Update Posted : July 26, 2016
Patients aged ≥70 years with acute myeloid leukemia (AML) have a poorer prognosis than those aged 60 to 69 years. The poor outcome is the result of treatment-related toxicity in elderly patients, owing to comorbidities, the greater possibility of other hematopoietic disorders, and a biologically poor risk prognosis. Anthracycline- and cytarabine-based therapy, administered for 3 and 7 days respectively (3 +7), remains the standard induction therapy for this patient population. This approach improved survival compared with supportive care (median, 5 vs. 3 months) for adults aged ≥ 65 years. However, the overall view has been that the results of intensive chemotherapy in elderly patients remain poor. Although complete remission (CR) rates of 40% to 80% can be achieved in highly selected populations, long-term survival has been poor. Furthermore, most clinical trials have only enrolled patients with an adequate performance status (PS).
Prognostic models have been developed from clinical trial data to predict the outcomes for older patients. However; each model relies on chronologic age. Age is a surrogate measure for both changes in tumor biology and patient characteristics. Understanding which patients are likely to benefit from intensive therapies versus low-intensity therapies or supportive care is critical. The definition of "fit" to undergo intensive induction therapy has not been established, and the therapeutic choice is mainly determined by physician and patient decision. In older patients, low-dose cytarabine (LD-AraC) has been demonstrated to be more beneficial than best supportive care and hydroxyurea. The recent availability of new drugs that could have an improved side effect profile and, in some cases, bioavailability might offer future improvement for this patient population. In this setting, the investigators have tended to consider, since 2007, patients aged ≥70 years as potential candidates for alternative lower intensity therapy (LD-AraC, hypomethylating agents) even when they presented in good physical condition.
The investigators goal was to determine whether age ≥ 70 years could represent a useful and simple cut off for treatment decision-making in clinical practice and whether low-intensity therapy could be an alternative therapeutic approach to intensive chemotherapy even for patients aged ≥ 70 years who were theoretically "fit" (WHO /ECOG/ PS of ≤ 2).
|Condition or disease||Intervention/treatment|
|Acute Myeloid Leukemia||Other: Age of patient|
|Study Type :||Observational|
|Actual Enrollment :||183 participants|
|Official Title:||Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia|
|Study Start Date :||January 2014|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||February 2015|
Intensive chemotherapy group
Group 1: Patients' age ≥ 70 years treated from 1985 to 1999 with intensive induction chemotherapy.
Other: Age of patient
Lower intensity treatment group
Group 2: patients treated from 2000 to 2006 with intensive chemotherapy plus improved supportive care and a follow-up protocol systematically performed at the university hospital.
Other: Age of patient
personalized treatment group
Group 3: patients who had received, starting in 2007, more "personalized" treatment with either intensive chemotherapy or lower-intensity therapy determined by the clinical judgment of the treating physician.
Other: Age of patient
- Overall survival (OS) [ Time Frame: Date of last contact if alive (up to 11 months) ]OS was the main endpoint for this analysis. The event for OS was death, and patients were censored at the date of last contact, if alive.
- Complete remission rate (CR) [ Time Frame: Date of last contact if alive or death (up to 11 months) ]A CR was defined according to standard criteria as < 5% blasts in bone marrow aspirates with evidence of maturation of cell lines and restoration of the peripheral blood counts.
- First Relapse [ Time Frame: Duration of the study (11 months) ]Hematologic relapse was considered when > 5% blasts were seen in 2 bone marrow aspirates obtained at a 15-day interval.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02844218
|Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet|
|Pierre-benite, France, 69310|
|Principal Investigator:||Xavier THOMAS, MD-PhD||Hospices Civils de Lyon - Centre Hospitalier Lyon Sud|